Genelux (NASDAQ:GNLX) Posts Earnings Results, Misses Expectations By $0.04 EPS

Genelux (NASDAQ:GNLX – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04), Zacks reports.

Genelux Stock Up 2.9%

Shares of NASDAQ GNLX traded up $0.06 during midday trading on Monday, hitting $1.92. 277,009 shares of the company’s stock were exchanged, compared to its average volume of 256,083. The firm has a market capitalization of $86.87 million, a PE ratio of -2.23 and a beta of 0.68. Genelux has a 12 month low of $1.77 and a 12 month high of $5.89. The company’s 50 day moving average price is $2.31 and its 200 day moving average price is $2.65.

Insiders Place Their Bets

In other Genelux news, insider Yong Yu sold 9,683 shares of the firm’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $2.75, for a total transaction of $26,628.25. Following the completion of the sale, the insider owned 258,688 shares of the company’s stock, valued at $711,392. This trade represents a 3.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Thomas Zindrick sold 34,463 shares of Genelux stock in a transaction on Monday, August 31st. The stock was sold at an average price of $2.67, for a total transaction of $92,016.21. Following the transaction, the chief executive officer directly owned 1,226,427 shares of the company’s stock, valued at approximately $3,274,560.09. This trade represents a 2.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 47,903 shares of company stock worth $126,320. 7.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genelux in a research report on Thursday, October 15th. Lucid Cap Mkts upgraded shares of Genelux to a “strong-buy” rating in a research note on Wednesday, September 16th. Benchmark restated a “speculative buy” rating on shares of Genelux in a research note on Tuesday, August 18th. Finally, Wall Street Zen upgraded Genelux from a “strong sell” rating to a “sell” rating in a report on Tuesday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $20.00.

Check Out Our Latest Stock Report on Genelux

About Genelux

(Get Free Report)

Genelux Corporation is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its research centers on engineered viruses designed to target and destroy cancer cells while stimulating an immune response against tumors. The company’s lead candidate is olvimulogene nanivacirepvec, also known as Olvi-Vec, an engineered vaccinia virus being studied in clinical trials for ovarian cancer and other solid tumors. Genelux is also advancing additional candidates based on its oncolytic virus platform.

Featured Stories

Earnings History for Genelux (NASDAQ:GNLX)

Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.